Clinical Trial Update: Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LT-02 (phosphatidylcholine) to placebo and mesalamine for maintenance of remission in ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• LT-02 (phosphatidylcholine) (phosphatidylcholine)
• Mesalamine (Mesalamine)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Ulcerative Colitis | Phase 3 | Status: COMPLETED